CL2014000604A1 - Compuestos derivados de dihidroquinolina-2-ona, inhibidores de aldosterona sintasa; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso para el tratamiento o profilaxis de enfermedad renal cronica, insuficiencia cardiaca congestiva, hipertension, aldosteronismo primario y sindrome de cushing. - Google Patents
Compuestos derivados de dihidroquinolina-2-ona, inhibidores de aldosterona sintasa; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso para el tratamiento o profilaxis de enfermedad renal cronica, insuficiencia cardiaca congestiva, hipertension, aldosteronismo primario y sindrome de cushing.Info
- Publication number
- CL2014000604A1 CL2014000604A1 CL2014000604A CL2014000604A CL2014000604A1 CL 2014000604 A1 CL2014000604 A1 CL 2014000604A1 CL 2014000604 A CL2014000604 A CL 2014000604A CL 2014000604 A CL2014000604 A CL 2014000604A CL 2014000604 A1 CL2014000604 A1 CL 2014000604A1
- Authority
- CL
- Chile
- Prior art keywords
- dihydroquinoline
- prophylaxis
- hypertension
- pharmaceutical composition
- treatment
- Prior art date
Links
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 title 1
- 206010007559 Cardiac failure congestive Diseases 0.000 title 1
- 208000016998 Conn syndrome Diseases 0.000 title 1
- 208000014311 Cushing syndrome Diseases 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 title 1
- 208000020832 chronic kidney disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000013846 primary aldosteronism Diseases 0.000 title 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011079673 | 2011-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014000604A1 true CL2014000604A1 (es) | 2014-10-17 |
Family
ID=46829775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014000604A CL2014000604A1 (es) | 2011-09-15 | 2014-03-13 | Compuestos derivados de dihidroquinolina-2-ona, inhibidores de aldosterona sintasa; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso para el tratamiento o profilaxis de enfermedad renal cronica, insuficiencia cardiaca congestiva, hipertension, aldosteronismo primario y sindrome de cushing. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9260408B2 (es) |
| EP (2) | EP3653618A1 (es) |
| JP (1) | JP6012735B2 (es) |
| KR (1) | KR101785143B1 (es) |
| CN (1) | CN103814021B (es) |
| AR (1) | AR087901A1 (es) |
| AU (1) | AU2012307509B2 (es) |
| BR (1) | BR112014006283B1 (es) |
| CA (1) | CA2846785C (es) |
| CL (1) | CL2014000604A1 (es) |
| CO (1) | CO6890099A2 (es) |
| CR (1) | CR20140091A (es) |
| DK (1) | DK2755963T3 (es) |
| EA (1) | EA035757B1 (es) |
| EC (1) | ECSP14013245A (es) |
| ES (1) | ES2763332T3 (es) |
| HR (1) | HRP20192323T1 (es) |
| HU (1) | HUE047771T2 (es) |
| IL (1) | IL231229A0 (es) |
| LT (1) | LT2755963T (es) |
| MX (1) | MX358376B (es) |
| MY (1) | MY169043A (es) |
| PE (1) | PE20141372A1 (es) |
| PL (1) | PL2755963T3 (es) |
| PT (1) | PT2755963T (es) |
| RS (1) | RS59737B1 (es) |
| SG (1) | SG11201400679WA (es) |
| SI (1) | SI2755963T1 (es) |
| TW (1) | TWI462914B (es) |
| UA (1) | UA111626C2 (es) |
| WO (1) | WO2013037779A1 (es) |
| ZA (1) | ZA201401884B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014135561A1 (en) * | 2013-03-08 | 2014-09-12 | F. Hoffmann-La Roche Ag | New dihydroquinoline-2-one derivatives as aldosterone synthase (cyp1 1 b2 or cyp1 1 b1 ) inhibitors |
| EP2970311A4 (en) | 2013-03-14 | 2016-11-23 | Brigham & Womens Hospital | BMP INHIBITORS AND METHODS OF USE |
| CN105073732B (zh) * | 2013-03-14 | 2017-07-21 | 豪夫迈·罗氏有限公司 | 用作醛固酮合酶抑制剂的二氢喹啉‑2‑酮衍生物 |
| MX2015011005A (es) * | 2013-03-14 | 2015-10-22 | Hoffmann La Roche | Derivados de dihidorquinolin-2-ona para usarse como inhibidores de aldoesterona sintasa. |
| US9181272B2 (en) | 2013-04-30 | 2015-11-10 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| CN105308045B (zh) * | 2013-05-27 | 2017-05-17 | 豪夫迈·罗氏有限公司 | 新的3,4‑二氢‑2h‑异喹啉‑1‑酮和2,3‑二氢‑异吲哚‑1‑酮化合物 |
| RS59663B1 (sr) * | 2013-05-27 | 2020-01-31 | Hoffmann La Roche | Nova jedinjenja 3,4-dihidro-2h-izokinolin-1-on i 2,3-dihidro-izoindol-1-on |
| JP6416229B2 (ja) | 2013-05-27 | 2018-10-31 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新しい３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物 |
| WO2015125858A1 (ja) * | 2014-02-24 | 2015-08-27 | 日本曹達株式会社 | ヘテロアリール化合物およびその用途 |
| WO2015148654A1 (en) * | 2014-03-26 | 2015-10-01 | The Brigham And Women's Hospital, Inc. | Compositions and methods for inhibiting bmp |
| MY176401A (en) * | 2014-04-24 | 2020-08-05 | Mitsubishi Tanabe Pharma Corp | Novel disubstituted 1,2,4-triazine compound |
| US10513521B2 (en) | 2014-07-15 | 2019-12-24 | The Brigham And Women's Hospital, Inc. | Compositions and methods for inhibiting BMP |
| JP6622300B2 (ja) * | 2014-10-31 | 2019-12-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規なジヒドロキノリンピラゾリル化合物 |
| WO2016066663A1 (en) * | 2014-10-31 | 2016-05-06 | F. Hoffmann-La Roche Ag | Pyrazolyl-3,4-dihydroquinolin-2-one aldosterone synthase inhibitors |
| WO2016066662A1 (en) * | 2014-10-31 | 2016-05-06 | F. Hoffmann-La Roche Ag | New dihydroquinoline pyrazolyl compounds as aldosterone synthase inhibitors |
| EP3344613B1 (en) | 2015-08-31 | 2020-03-04 | Dong-A Socio Holdings Co., Ltd. | Heteroaryl compounds and their use as therapeutic drugs |
| JP6314196B2 (ja) * | 2015-10-22 | 2018-04-18 | 田辺三菱製薬株式会社 | 医薬組成物 |
| US10717731B2 (en) | 2015-10-23 | 2020-07-21 | Mitsubishi Tanabe Pharma Corporation | Nitrogen-containing aromatic heterocyclic compound |
| US10913730B2 (en) | 2016-10-10 | 2021-02-09 | Dong-A Socio Holdings Co., Ltd. | Heteroaryl compounds and their use as Mer inhibitors |
| DK3551627T3 (da) * | 2016-12-08 | 2022-04-19 | Hoffmann La Roche | Nye isoxazolyletherderivater som gaba a alpha5-pam |
| WO2020223267A1 (en) | 2019-05-01 | 2020-11-05 | Boehringer Ingelheim International Gmbh | (r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate |
| WO2023063851A1 (en) * | 2021-10-13 | 2023-04-20 | «Target Medicals» Limited Liability Company | Inhibitors of human aldosterone synthase (cyp11b2) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8334282D0 (en) * | 1983-12-22 | 1984-02-01 | Pfizer Ltd | Quinolone inotropic agents |
| US4710507A (en) * | 1983-12-22 | 1987-12-01 | Pfizer Inc. | Quinolone inotropic agents |
| CN85100796A (zh) * | 1985-04-01 | 1986-10-01 | 辉瑞公司 | 喹啉酮衍生物的制备方法 |
| FR2580646A1 (fr) * | 1985-04-19 | 1986-10-24 | Synthelabo | Derives de 2(1h)-quinolinone, leur preparation et leur application en therapeutique |
| US20080176830A1 (en) | 2005-04-14 | 2008-07-24 | Adams Nicholas D | Compounds, Compositions, and Methods |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| AU2010247391A1 (en) | 2009-05-15 | 2011-12-01 | Novartis Ag | Benzoxazolone derivatives as aldosterone synthase inhibitors |
| MA33358B1 (fr) | 2009-05-15 | 2012-06-01 | Novartis Ag | Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase |
| US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
-
2012
- 2012-09-12 KR KR1020147009761A patent/KR101785143B1/ko active IP Right Grant
- 2012-09-12 EA EA201490596A patent/EA035757B1/ru not_active IP Right Cessation
- 2012-09-12 HU HUE12756741A patent/HUE047771T2/hu unknown
- 2012-09-12 CA CA2846785A patent/CA2846785C/en active Active
- 2012-09-12 MX MX2014002770A patent/MX358376B/es active IP Right Grant
- 2012-09-12 PE PE2014000328A patent/PE20141372A1/es active IP Right Grant
- 2012-09-12 AU AU2012307509A patent/AU2012307509B2/en active Active
- 2012-09-12 MY MYPI2014700616A patent/MY169043A/en unknown
- 2012-09-12 CN CN201280045041.1A patent/CN103814021B/zh active Active
- 2012-09-12 WO PCT/EP2012/067744 patent/WO2013037779A1/en active Application Filing
- 2012-09-12 LT LTEP12756741.0T patent/LT2755963T/lt unknown
- 2012-09-12 PL PL12756741T patent/PL2755963T3/pl unknown
- 2012-09-12 RS RS20191655A patent/RS59737B1/sr unknown
- 2012-09-12 DK DK12756741.0T patent/DK2755963T3/da active
- 2012-09-12 ES ES12756741T patent/ES2763332T3/es active Active
- 2012-09-12 TW TW101133381A patent/TWI462914B/zh active
- 2012-09-12 PT PT127567410T patent/PT2755963T/pt unknown
- 2012-09-12 EP EP19204552.4A patent/EP3653618A1/en active Pending
- 2012-09-12 SI SI201231713T patent/SI2755963T1/sl unknown
- 2012-09-12 BR BR112014006283-8A patent/BR112014006283B1/pt active IP Right Grant
- 2012-09-12 JP JP2014530184A patent/JP6012735B2/ja active Active
- 2012-09-12 SG SG11201400679WA patent/SG11201400679WA/en unknown
- 2012-09-12 EP EP12756741.0A patent/EP2755963B1/en active Active
- 2012-09-13 US US13/612,956 patent/US9260408B2/en active Active
- 2012-09-17 AR ARP120103420A patent/AR087901A1/es active IP Right Grant
- 2012-12-09 UA UAA201404030A patent/UA111626C2/uk unknown
-
2014
- 2014-02-25 CR CR20140091A patent/CR20140091A/es unknown
- 2014-02-26 CO CO14040934A patent/CO6890099A2/es unknown
- 2014-02-27 IL IL231229A patent/IL231229A0/en active IP Right Grant
- 2014-03-13 CL CL2014000604A patent/CL2014000604A1/es unknown
- 2014-03-14 EC ECSP14013245 patent/ECSP14013245A/es unknown
- 2014-03-14 ZA ZA201401884A patent/ZA201401884B/en unknown
-
2019
- 2019-12-23 HR HRP20192323TT patent/HRP20192323T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014000604A1 (es) | Compuestos derivados de dihidroquinolina-2-ona, inhibidores de aldosterona sintasa; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso para el tratamiento o profilaxis de enfermedad renal cronica, insuficiencia cardiaca congestiva, hipertension, aldosteronismo primario y sindrome de cushing. | |
| CL2014001389A1 (es) | Compuestos derivados biciclicos de dihidroisoquinolin-1-ona; proceso de obtencion; composicion faramceutica; y su uso para el tratamiento o la profilaxis de enfermedades renales cronicas, fallo cardiaco congestivo, hipertension, aldosteronismo primario y sindrome de cushing. | |
| EA201790765A1 (ru) | Производные спиродиамина в качестве ингибиторов альдостерон-синтазы | |
| CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| EA201591420A1 (ru) | Гетероарильные соединения и их применение | |
| EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| LTC2924034I2 (lt) | Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių | |
| CL2014001779A1 (es) | Compuestos derivados de pirimidinas y triazinas fusionadas sustituidas; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento y/o prevencion de insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades. | |
| CL2015001279A1 (es) | Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras. | |
| WO2012122383A3 (en) | Pi3 kinase inhibitors and uses thereof | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| EA201691421A1 (ru) | Гетероарилы и их применение | |
| EA201492223A1 (ru) | Новые диазаспироциклоалканы и азаспироциклоалканы | |
| DK2242750T3 (da) | Konformationelt begrænsede biphenyl-derivater til anvendelse som hepatitis C-virusinhibitorer | |
| CL2014000504A1 (es) | Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades. | |
| CL2014000459A1 (es) | Compuestos derivados de heterociclos biciclicos con nitrogeno; composicion farmaceutica; uso para tratar la hipertension arterial pulmonar. | |
| CL2013000104A1 (es) | Compuestos derivados de heterociclicos nitrogenados sustituidos, agonistas del receptor ip; composicion farmaceutica; combinación farmaceutica; y uso para el tratamiento de la hipertension arterial pulmonar. | |
| DK2455374T3 (da) | Fremgangsmåde til fremstillingen af forbindelser der kan anvendes som inhibitorer af SGLT | |
| EA201171151A1 (ru) | Кристаллические трипептидные ингибиторы эпоксикетон-протеазы | |
| CL2013001141A1 (es) | Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c. | |
| CL2014003031A1 (es) | Compuestos derivados de uracilo sustituidos biciclicamente; procedimiento de preparacion; composicion farmaceutica; uso para tratar y/o prevenir insuficiencia cardiaca, hipertension pulmonar, epoc, asma, nefropatia, entre otras. | |
| CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
| CL2013003686A1 (es) | Compuestos derivados de ergolina, antagonista del receptor de 5-ht1d; útiles para el tratamiento de la migraña. |